Your browser doesn't support javascript.
loading
Donor leukocyte infusion--the effect of mutual reactivity of donor's and recipient's peripheral blood mononuclear cells on hematopoietic progenitor cells growth.
Petakov, M; Balint, B; Bugarski, D; Jovcic, G; Stojanovic, N; Vojvodic, D; Todoric, B; Stamatovic, D; Taseski, J; Malesevic, M.
Afiliación
  • Petakov M; Military Medical Academy, Institute for Medical Research, Institute of Transfusiology, Yugoslavia.
Vojnosanit Pregl ; 57(5): 89-93, 2000.
Article en En | MEDLINE | ID: mdl-11213681
ABSTRACT
Donor leukocyte infusions are an effective therapy for patients who relapse with leukemia after bone marrow transplantation. We report the case of 14-year-old boy who relapsed 34 months after sibling donor bone marrow transplant for Philadelphia-positive chronic myeloid leukemia. Subsequently, he received three infusions of donor mononuclear cells (DMNC) harvested in steady state hematopoiesis and one G-CSF mobilized-peripheral blood mononuclear cells (PBMC) infusion. Simultaneously, test named as--"Test of Mixed Progenitors" (TMP) was performed for the assessment whether the outcome of donor leukocyte infusion treatment could be predicted. Prior to DMNC infusions, the CFU-GM and BFU-E colony assays were performed for donor's and recipient's PBMC individually, as well as for the mixture of these cells at 11 ratio. The cells were plated either directly in the semisolid medium or after 24 h preincubation treatment. Significantly lower values for CFU-GM derived colonies were determined in TMP in comparison to the CFU-GM values obtained for the recipient's cells. The reduced number of CFU-GM was determined both in TMP performed without preincubation treatment, app. 80% and after the 24 h preincubation, app. 55%. The reduced number of BFU-E derived colonies (app. 44%) was observed only related to recipient's cells and after the preincubation treatment of the cells. The patient did not develop GVHD and currently (40 months after the first infusion). He remained well in complete hematological, cytogenetic, molecular and clinical remission, which was the most direct evidence of the GVL effect. The novel in vitro TMP test in which the specific contribution of donor's leukocytes to the growth of recipient's hematopoietic precursor cell growth was determined, correlated with the clinical outcome.
Asunto(s)
Buscar en Google
Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Trasplante de Médula Ósea / Transfusión de Leucocitos / Acondicionamiento Pretrasplante Tipo de estudio: Prognostic_studies Idioma: En Revista: Vojnosanit Pregl Año: 2000 Tipo del documento: Article
Buscar en Google
Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Trasplante de Médula Ósea / Transfusión de Leucocitos / Acondicionamiento Pretrasplante Tipo de estudio: Prognostic_studies Idioma: En Revista: Vojnosanit Pregl Año: 2000 Tipo del documento: Article